Emerging Markets Earnings Roundup: Merck, AstraZeneca (Part 6)
This article was originally published in PharmAsia News
Merck comes up short on goal to reach 25% of total sales from emerging markets and sees headwinds on diabetes. AstraZeneca is full-steam ahead on China with headcount expansion in 2013 paving the way for gains in 2014, CEO Pascal Soriot says.
You may also be interested in...
AstraZeneca Says Revamped Pipeline Will Return It To Health, But Pitfalls Remain
Equipped with 19 drug candidates for Phase III trials over the next two years, Britain’s AstraZeneca says it’s finally “on a roll.” But the troubled medicine maker still expects earnings to keep falling in 2014 amid uncertainty over heart drug Brilinta and likely generic competition to Nexium in the U.S.
Pushing Hard On PD-1, Merck Signs Trio Of Combo Development Deals
Merck’s oncology build-up is continuing, even as it tightens focus and squeezes spending in other parts of its business as part of an ongoing “reshaping” that CFO Peter Kellogg said will help to maximize “core in-line assets and key pipeline programs” that are critical for growth.
List Ahead For Southeast Asia Pharma In 2015
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.